<DOC>
	<DOCNO>NCT01966133</DOCNO>
	<brief_summary>Investigators hypothesise use transarterial chemoembolisation ( TACE ) liver resection patient hepatocellular carcinoma eradicate residual cancer cell liver thus improve survival patient high risk factor residual tumor . The aim study compare survival patient high risk factor residual tumor undergo liver resection plus post-operative TACE versus liver resection alone .</brief_summary>
	<brief_title>TACE Adjuvant Therapy After Hepatectomy HCC</brief_title>
	<detailed_description>Liver resection mainstay curative treatment hepatocellular carcinoma ( HCC ) . However , recurrence common surgery occur liver , especially patient high risk factor residual tumor , tumor diameter 5 cm , multiple nodule , microvascular invasion . Transarterial chemoembolisation ( TACE ) effective palliative treatment HCC . It involve infusion chemotherapeutic agent admix iodised oil follow embolisation hepatic arterial flow use small particle . This procedures allow application small dose chemotherapy concentrate liver thus well tolerate minimal side effect . The main complication TACE liver function damage , mild feverish symptom , vomit , etc . But reversible . We conduct randomise controlled trial evaluate efficacy use TACE hepatectomy HCC patient high risk factor residual tumor ( tumor diameter 5 cm , multiple nodule , microvascular invasion ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>HCC patient receive curative hepatectomy negative resection margin Tumors diameter 5 cm , multiple nodule , microvascular invasion define high risk factor residual tumor use patient stratification . Age 18 70 ChildPugh class A ASA class I III ECOG performance status Grade 0 1 Patients receive concomitant local ablation previous TACE Main portal vein tumour thrombus extraction hepatectomy Tumour arise caudate lobe Presence extrahepatic disease Impaired liver function either clinically detect ascites , hepatic encephalopathy , serum albumin &lt; 25g/L bilirubin &gt; 50micromol/L Renal impairment creatinine &gt; 200micromol/L Severe concurrent medical illness persist &gt; 6 week hepatectomy History cancer Hepatic artery anomaly make TACE possible Allergy doxorubicin lipiodol Pregnant woman Informed consent available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HCC</keyword>
	<keyword>Randomised control trial</keyword>
	<keyword>TACE</keyword>
	<keyword>Resection</keyword>
</DOC>